Month: April 2016

  • BREXIT 2.0

    Although I have already flagged up the special situation for R & D companies, Brexit continues to be a double edged sword and this will continue long after President Obama flies off from Stansted later today.

    For many Companies, the Brexit decision is reactive and fairly uncomplicated; for others, the main challenge from ‘Brexit’ is the uncertainty which may well soon be over after 23 June. But for R & D companies, the unknowns spread across a range of interlinked areas; from pure financial markets and future market places, to academia and intellectual property registration and governance to Grant and State Aid for research and development projects.

    The Pharmaceutical industry in particular, can attribute significant amounts of its growth marketplaces to the US and non EU territories, [as compared to an 8% slump in UK > EU sales]. But what is the impact on the EU Academic network were the UK to remove itself both as a centre of excellence and as a sponsor institution for the MHRA and NICE.
    Read more about the special situation for Pharma here:

    http://www.pharmafile.com/news/502948/what-would-brexit-mean-pharmahttp://www.pharmafile.com/news/502948/what-would-brexit-mean-pharma

  • UKSPA Conference May 2016

    Maria Kitt has been invited to join David Hardman (Chairman UK Science Park Association and Nicky Morgan MP) on 19 and 20 May. The Conference will catch up with a range of updates from the scientific and innovation community. Maria speaks upon the impact of ‘Brexit’ on innovative companies and the potential opportunities ahead.
    Register and further information can be found here……..
    http://www.ukspa.org.uk/our-organisation/ukspa-events/ukspa-may-conference

    [ba-pdfviewer pdfurl=”https://taxinsightuk.com/wp-content/uploads/2016/04/UKSPA-Programmev6.pdf” width=”100%” height=”800px”]